10-K: BiomX Inc. Reports 2024 Annual Results, Highlights Clinical Progress and Financial Position

BiomX Inc. files its 2024 10-K, detailing clinical advancements in phage therapy for cystic fibrosis and diabetic foot osteomyelitis, alongside its financial status and future outlook.

Summary

• BiomX Inc., a clinical-stage company, is focused on developing phage therapies for chronic diseases.
• The company's lead programs target cystic fibrosis (CF) and diabetic foot osteomyelitis (DFO).
• In 2024, BiomX reported a net loss of $17.7 million, compared to a net loss of $26.2 million in 2023.
• As of December 31, 2024, BiomX had $18 million in cash, cash equivalents, and restricted cash.
• The company anticipates its current cash resources will fund operations into the first quarter of 2026.
• BiomX acquired Adaptive Phage Therapeutics (APT) in March 2024, expanding its intellectual property portfolio.
• A Phase 2b study for BX004 in CF patients is expected to begin in the second quarter of 2025, with topline results anticipated in the first quarter of 2026.
• Topline results for the Phase 2 study of BX211 in DFO are expected in the first quarter of 2025.
• The company is exploring the use of Real-World Evidence (RWE) to support future regulatory filings.
• BiomX is also supporting an NIH study targeting P. Aeruginosa infections in CF patients.
• The development of a personalized phage therapy for Prosthetic Joint Infections (PJI) is currently on hold.
• The company discontinued the development of BX005 for Atopic Dermatitis (AD) to focus on CF and DFO programs.
• BiomX relies on third parties for manufacturing and clinical trial execution.
• The company's headquarters and key operations are located in Israel, which poses risks related to political and military instability.
• BiomX is subject to various healthcare laws and regulations, including anti-kickback and false claims statutes.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there's clinical progress and a decrease in net loss, the going concern warning and need for future capital raises temper the positive aspects.

Positives

• Net loss decreased from $26.2 million in 2023 to $17.7 million in 2024.
• FDA granted Fast Track and Orphan Drug designations for BX004.
• Acquisition of Adaptive Phage Therapeutics enhances intellectual property.
• Exploring Real-World Evidence (RWE) for regulatory filings could streamline approval processes.

Negatives

• The company has incurred losses since its inception and expects to continue incurring significant losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has never generated any revenue from product sales and may never be profitable.
• Development of a personalized phage therapy for Prosthetic Joint Infections (PJI) is currently on hold.
• The company discontinued the development of BX005 for Atopic Dermatitis (AD) to focus on CF and DFO programs.

Risks

• The company will need to raise additional capital in the future to support its operations.
• The company is seeking to develop product candidates using phage technology, an approach for which it is difficult to predict the potential success and time and cost of development.
• Clinical trials may fail to demonstrate the requisite safety and efficacy for drug products, or safety, purity, and potency for biologics, and any of the company's product candidates could cause adverse effects.
• The company's headquarters, research and development and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel.
• The company's product candidates rely on the availability of specialty raw materials, which may not be available to it on acceptable terms or at all.
• The market price of the company's Common Stock and other securities may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of the company's Common Stock.

Future Outlook

BiomX expects to continue incurring significant expenses as it advances its product candidates and seeks regulatory approval. The company anticipates its current cash resources will fund operations into the first quarter of 2026 and will need to raise additional capital in the future.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, strong competition and an emphasis on proprietary products. BiomX faces competition from larger pharmaceutical companies, specialty biotechnology companies, academic research institutions, governmental agencies, as well as public and private institutions.

Comparison to Industry Standards

• The document mentions competitors like Locus Biosciences, Inc., Armata Pharmaceuticals, Inc. and SNIPR Biome, which are also developing bacteriophage products.
• It also lists investigational and marketed products for CF (Trikafta, Symdeco, Pulmozyme, Tobramycin, Aztreonam) and DFO (TP-102 by Technophage, a phage-based product by Phaxiam), providing a benchmark of existing treatments.

Related Party Transactions

• A Securities Purchase Agreement was entered into on March 6, 2024 with certain investors, including CFF, Orbimed and Telmina Limited, each of which hold more than 5% of our outstanding Common Stock.
• The February 2025 SPA and the Inducement Letter Agreements and other agreements related to the February 2025 Financing with certain investors, including Deerfield, CFF, Nantahala Capital Management, LLC, or Nantahala, and AIGH Investment Partners, LP, or AIGH, each of which holds more than 5% of our outstanding Common Stock.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may experience uncertainty due to the company's financial situation and potential cost reduction strategies.
• Patients with CF and DFO could benefit from successful development of phage therapies.
• Suppliers and creditors face risks associated with the company's ability to meet its financial obligations.

Next Steps

• Initiate a randomized, double blind, placebo-controlled, multi-center Phase 2b study in CF patients with chronic P. aeruginosa pulmonary infections in the second quarter of 2025.
• Readout of study topline results is expected at week 13 evaluating healing of the wound associated with osteomyelitis, and is expected in the first quarter of 2025.
• Anticipate further discussion with the FDA and European Committee for Medicinal Products for Human Use, or CHMP, in 2025 to discuss our proposed plan to use RWE to support potential future regulatory filings.

Key Dates

Keywords

phage therapy, cystic fibrosis, diabetic foot osteomyelitis, clinical trials, bacteriophage, BiomX, BX004, BX211, DFO, CF, FDA, RWE, APT, BOLT, PST